Fluctuations in patient serum sodium levels are common after aneurysmal subarachnoid hemorrhage (aSAH), but their effect on patient outcome is not well described in the literature. The goal of this work was to better characterize the relationship between fluctuations in serum sodium levels, outcome, and the development of delayed cerebral ischemia (DCI) after aSAH.
The authors performed a post hoc analysis of data from the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial. Patients had their serum sodium values recorded daily for 14 days post-aSAH. Average and average absolute daily differences in sodium levels were calculated for each patient based on 3 reference points: admission sodium levels, a normal sodium level (defined as 140 mmol/L), and the previous day’s sodium level. These variables were also calculated for the classic “vasospasm window” (days 3–12) post-aSAH. A stepwise logistic regression model, locally weighted scatterplot smoothing curves, and receiver operator characteristic curve analysis were used to evaluate the relationship between alterations in serum sodium levels and clinical outcome or the development of DCI after aSAH. Poor outcome was defined as a modified Rankin Scale (mRS) score of > 2 at 3 months.
The average daily difference in sodium values from baseline (p < 0.001), average daily difference from a normal sodium level (p < 0.001), average absolute daily difference from a normal sodium level (p = 0.015), and average absolute daily difference from the previous day’s sodium level (p = 0.017) were significant predictors of poor outcome in a stepwise multivariate regression model. There was a trend toward significance for average absolute daily difference from admission sodium levels during the vasospasm window as an independent predictor of DCI (p = 0.052). There was no difference in the predictive capacity for DCI when sodium fluctuations from post-aSAH days 1–14 were compared with those from the classic vasospasm window (days 3–12).
Fluctuations in serum sodium levels may play a role in clinical outcome and the development of DCI after aSAH. The timing of these fluctuations appears to have no significant effect on the development of DCI.
ABBREVIATIONSaSAH = aneurysmal subarachnoid hemorrhage; CONSCIOUS-1 = Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage; DCI = delayed cerebral ischemia; LOWESS = locally weighted scatterplot smoothing; mRS = modified Rankin Scale; WFNS = World Federation of Neurosurgical Societies.
Correspondence Matthew E. Eagles: University of Calgary, AB, Canada. email@example.com.
INCLUDE WHEN CITING Published online August 17, 2018; DOI: 10.3171/2018.3.JNS173068.
Disclosures Dr. Macdonald reports ownership of Edge Therapeutics, Inc. and receiving non–study-related clinical or research effort support from the Brain Aneurysm Foundation, Heart and Stroke Foundation of Canada, Canadian Institutes for Health Research, and Physicians Services Incorporated Foundation.
BalesJ, ChoS, TranTK, KorabGA, KhandelwalN, SpiekermanCF, : The effect of hyponatremia and sodium variability on outcomes in adults with aneurysmal subarachnoid hemorrhage. 96:340–349, 20162763716510.1016/j.wneu.2016.09.005)| false
BeseogluK, EtminanN, SteigerHJ, HänggiD: The relation of early hypernatremia with clinical outcome in patients suffering from aneurysmal subarachnoid hemorrhage. 123:164–168, 201410.1016/j.clineuro.2014.05.02224956546)| false
DiringerMNBleckTPClaude HemphillJIIIMenonDShutterLVespaP: Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care15:211–2402011
DiringerMN, BleckTP, Claude HemphillJIII, MenonD, ShutterL, VespaP, : Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. 15:211–240, 201110.1007/s12028-011-9605-921773873)| false
FeiginVL, LawesCMM, BennettDA, Barker-ColloSL, ParagV: Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. 8:355–369, 20091923372910.1016/S1474-4422(09)70025-0)| false
MapaBTaylorBESAppelboomGBruceEMClaassenJConnollyESJr: Impact of hyponatremia on morbidity, mortality, and complications after aneurysmal subarachnoid hemorrhage: a systematic review. World Neurosurg85:305–3142016
MapaB, TaylorBES, AppelboomG, BruceEM, ClaassenJ, ConnollyESJr: Impact of hyponatremia on morbidity, mortality, and complications after aneurysmal subarachnoid hemorrhage: a systematic review. 85:305–314, 20162636132110.1016/j.wneu.2015.08.054)| false
NakagawaIKurokawaSNakaseH: Hyponatremia is predictable in patients with aneurysmal subarachnoid hemorrhage—clinical significance of serum atrial natriuretic peptide. Acta Neurochir (Wien)152:2147–21522010
SakrY, RotherS, FerreiraAM, EwaldC, DünischP, RiedemmannN, : Fluctuations in serum sodium level are associated with an increased risk of death in surgical ICU patients. 41:133–142, 201310.1097/CCM.0b013e318265f57623128383)| false
SherlockM, O’SullivanE, AghaA, BehanLA, RawlukD, BrennanP, : The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. 64:250–254, 200610.1111/j.1365-2265.2006.02432.x16487432)| false
WartenbergKE, SchmidtJM, ClaassenJ, TemesRE, FronteraJA, OstapkovichN, : Impact of medical complications on outcome after subarachnoid hemorrhage. 34:617–624, 20061652125810.1097/01.CCM.0000201903.46435.35)| false
ZhengBQiuYJinHWangLChenXShiC: A predictive value of hyponatremia for poor outcome and cerebral infarction in high-grade aneurysmal subarachnoid haemorrhage patients. J Neurol Neurosurg Psychiatry82:213–2172011
ZhengB, QiuY, JinH, WangL, ChenX, ShiC, : A predictive value of hyponatremia for poor outcome and cerebral infarction in high-grade aneurysmal subarachnoid haemorrhage patients. 82:213–217, 201110.1136/jnnp.2009.18034920667862)| false